Vivos Therapeutics Stock Performance
| VVOS Stock | USD 4.61 0.16 3.60% |
Vivos Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The entity has a beta of 0.22, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Vivos Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vivos Therapeutics is expected to be smaller as well. Use Vivos Therapeutics treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to analyze future returns on Vivos Therapeutics.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Vivos Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting basic indicators, Vivos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.6 | Five Day Return 7.21 | Year To Date Return (60.93) | Ten Year Return (97.95) | All Time Return (97.95) |
Last Split Factor 1:25 | Last Split Date 2023-10-27 |
1 | Acquisition by Huntsman Ronald Kirk of 5000 shares of Vivos Therapeutics at 4.31 subject to Rule 16b-3 | 11/08/2024 |
2 | Vivos Therapeutics Inc Reports Q3 2024 EPS of -0.40, Beating Estimates Revenue Reaches 3. ... | 11/14/2024 |
3 | Vivos Therapeutics, Inc. Q3 2024 Earnings Call Transcript | 11/15/2024 |
4 | Vivos Therapeutics price target lowered to 6 from 8.25 at Alliance Global Partners - TipRanks | 11/19/2024 |
5 | Acquisition by Bradford Amman of 149533 shares of Vivos Therapeutics at 2.64 subject to Rule 16b-3 | 11/26/2024 |
| Begin Period Cash Flow | 3.5 M |
Vivos |
Vivos Therapeutics Relative Risk vs. Return Landscape
If you would invest 280.00 in Vivos Therapeutics on September 17, 2024 and sell it today you would earn a total of 181.00 from holding Vivos Therapeutics or generate 64.64% return on investment over 90 days. Vivos Therapeutics is currently generating 1.0771% in daily expected returns and assumes 8.1757% risk (volatility on return distribution) over the 90 days horizon. In different words, 72% of stocks are less volatile than Vivos, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vivos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vivos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vivos Therapeutics, and traders can use it to determine the average amount a Vivos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1318
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VVOS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.18 actual daily | 72 72% of assets are less volatile |
Expected Return
| 1.08 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Vivos Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vivos Therapeutics by adding it to a well-diversified portfolio.
Vivos Therapeutics Fundamentals Growth
Vivos Stock prices reflect investors' perceptions of the future prospects and financial health of Vivos Therapeutics, and Vivos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vivos Stock performance.
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | (0.86) % | ||||
| Operating Margin | (0.48) % | ||||
| Current Valuation | 17.62 M | ||||
| Shares Outstanding | 4.84 M | ||||
| Price To Book | 2.91 X | ||||
| Price To Sales | 1.59 X | ||||
| Revenue | 13.8 M | ||||
| EBITDA | (16.68 M) | ||||
| Cash And Equivalents | 17.83 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 2 M | ||||
| Debt To Equity | 0.10 % | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (11.95 M) | ||||
| Earnings Per Share | (4.99) X | ||||
| Total Asset | 10.73 M | ||||
| Retained Earnings | (93.05 M) | ||||
About Vivos Therapeutics Performance
Assessing Vivos Therapeutics' fundamental ratios provides investors with valuable insights into Vivos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vivos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea , and snoring in adults. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado. Vivos Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 165 people.Things to note about Vivos Therapeutics performance evaluation
Checking the ongoing alerts about Vivos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vivos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vivos Therapeutics is way too risky over 90 days horizon | |
| Vivos Therapeutics appears to be risky and price may revert if volatility continues | |
| Vivos Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.8 M. Net Loss for the year was (13.58 M) with profit before overhead, payroll, taxes, and interest of 12.6 M. | |
| Vivos Therapeutics currently holds about 17.83 M in cash with (11.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77. | |
| Latest headline from news.google.com: Vivos Therapeutics price target lowered to 6 from 8.25 at Alliance Global Partners - TipRanks |
- Analyzing Vivos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vivos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Vivos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vivos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vivos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vivos Therapeutics' stock. These opinions can provide insight into Vivos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.